3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
33
Radiotherapy
19
Temozolomide
16
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
7
Cyclophosphamide
7
trastuzumab deruxtecan
4
temsirolimus
4
Sunitinib
4
Specimen Handling
4
Mental Status and Dementia Tests
4
motexafin gadolinium
3
fludarabine phosphate
3
fludarabine
3
aldesleukin
3
Trastuzumab
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Dexamethasone
3
Capecitabine
3
Bevacizumab
3
pembrolizumab
2
entrectinib
2
efaproxiral
2
Vinorelbine
2
Topotecan
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Quality of Life
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled